Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
42462708 2026 PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma. Cancer cell Likely relevant Investigates the mechanism of perioperative anti-PD-1 therapy in patients and mice, measuring B cell responses, antibody repertoires, and complement activation. anti-PD-1 Mixed hepatocellular carcinoma anti-PD-1 14/36/0 Awaiting curator check
42497523 2026 Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy. Phytomedicine : international journal of phytotherapy and phytopharmacology Likely relevant The study experimentally tests a novel small-molecule PD-L1 inhibitor (rosavin) in tumor-bearing mouse models and measures its effects on antitumor immunity and CD8+ T cell activation. rosavin Animal melanoma and colon cancer rosavin 0/0/0 Awaiting curator check
42541926 2026 Intratumoural plasma cells mediate a pro-inflammatory response to kinase inhibition and successful immune checkpoint blockade therapy in malignant peripheral nerve sheath tumours. EBioMedicine Likely relevant The study experimentally tests CDK4/6 inhibitors, MEK inhibitors, and anti-PD-L1 therapy in tumour-bearing mice and reports their effects on various immune cell populations and antigen presentation. anti-PD-L1; CDK4/6 inhibitors; MEK inhibitors Animal Malignant peripheral nerve sheath tumours anti-PD-L1 0/15/0; CDK4/6 inhibitors 0/0/0; MEK inhibitors 9/0/0 Awaiting curator check
42557318 2026 Membranolytic peptide programs immunogenic cell death for cancer therapy. Nature Likely relevant Tests a synthetic membranolytic peptide and immune checkpoint blockade in mice, measuring immunogenic cell death, MHC class I antigen presentation, and T cell activation. aMPC16-CA50; immune checkpoint blockade Animal unspecified tumour aMPC16-CA50 0/0/0; immune checkpoint blockade 0/1/0 Awaiting curator check
42558624 2026 Targeting NOP14 remodels the tumor immune microenvironment and enhances the antitumor efficacy of PD-1 blockade in DLBCL. Frontiers in immunology Likely relevant The study experimentally tests NOP14-siRNA@LNP and anti-PD-1 blockade in DLBCL cell lines and a syngeneic mouse model, measuring CD8+ T cell infiltration, activation, and PD-L1 expression. anti-PD-1; NOP14-siRNA@LNP Mixed Diffuse large B-cell lymphoma (DLBCL) anti-PD-1 14/36/0; NOP14-siRNA@LNP 0/0/0 Awaiting curator check
42564317 2026 Dual-targeting CD73/PD-L1 bifunctional inhibitor: a promising cancer immunotherapy strategy. Frontiers in immunology Likely relevant The study tests a novel bifunctional small molecule (CP-1) targeting PD-L1 and CD73 and measures its immunomodulatory and T cell functional effects using cell assays. CP-1 Cell line unspecified CP-1 0/0/0 Awaiting curator check
42587106 2026 Targeting the SELP/PSGL1 axis reprograms M2 macrophages and enhances anti-PD-1 efficacy in gastric cancer. Oncogene Likely relevant The study tests the pharmacological targeting of SELP with KF38789 and PD-1 blockade in syngeneic models and measures macrophage polarization and CD8+ T-cell infiltration. KF38789; PD-1 blockade Animal gastric cancer KF38789 0/0/0; PD-1 blockade 0/0/0 Awaiting curator check
42643393 2026 Photodynamic priming enhances anti-PD1 therapy responses in patient-derived pancreatic cancer organoid immune cocultures. Frontiers in immunology Likely relevant The study tests photodynamic priming and pembrolizumab in patient-derived pancreatic cancer organoids and immune cocultures, measuring DAMP expression, dendritic cell activation, and T cell activation markers. Visudyne; pembrolizumab Cell line pancreatic ductal adenocarcinoma Visudyne 0/0/0; pembrolizumab 0/0/16 Awaiting curator check
42644613 2026 Targeting ERO1A Enhances Antitumor Immune Response by Recruiting CD8+ T Cells and Synergizing with PD-L1 Blockade in Liver Cancer. Cancer immunology research Likely relevant The study tests an ERO1A inhibitor and PD-L1 inhibitor in liver cancer animal models and reports CD8+ T-cell infiltration, function, chemokine secretion, and checkpoint/MHC expression. ERO1A inhibitor; PD-L1 inhibitor Animal liver cancer ERO1A inhibitor 0/0/0; PD-L1 inhibitor 0/0/0 Awaiting curator check
42805760 2026 Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer. Journal for immunotherapy of cancer Likely relevant The study investigates the temporal dynamics of the immune response in prostate cancer patients treated with neoadjuvant androgen deprivation therapy and its implications for checkpoint inhibitor therapy, measuring various immune cell infiltrates and pathways. androgen deprivation therapy; checkpoint inhibitor Patient prostate cancer androgen deprivation therapy 0/0/0; checkpoint inhibitor 0/0/0 Awaiting curator check
42875546 2026 Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy. Nature immunology Likely relevant The study tests pharmacological or genetic PPARδ activation in combination with checkpoint blockade and evaluates CD8+ T cell fitness and function. checkpoint blockade Mixed colorectal cancer checkpoint blockade 0/1/0 Awaiting curator check
39531509 2025 The circRNA cEMSY Induces Immunogenic Cell Death and Boosts Immunotherapy Efficacy in Lung Adenocarcinoma. Cancer research Likely relevant The study tests lipid nanoparticle-encapsulated cEMSY and PD-1 blockade in lung adenocarcinoma models, measuring immunogenic cell death, damage-associated molecular patterns, and immune cell infiltration. PD-1 blockade Mixed lung adenocarcinoma PD-1 blockade 0/0/0 Awaiting curator check
39571582 2025 A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden. Cell chemical biology Likely relevant The study experimentally tests a yeast-based therapeutic delivering an immune checkpoint inhibitor in a mouse model and reports shifts in the immune cell profile. Sb_haPD-1 Animal colorectal cancer Sb_haPD-1 0/0/0 Awaiting curator check
39633050 2025 Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature Likely relevant Tests pharmacological inhibitors of adenosine A2A receptors and anti-CSF1R/PD-L1 in mice and patient samples, measuring CD8+ T cell activity and macrophage abundance. anti-CSF1R antibody; ciforadenant; atezolizumab Mixed prostate cancer anti-CSF1R antibody 0/0/0; ciforadenant 0/0/0; atezolizumab 0/0/4 Awaiting curator check
39663448 2025 Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature Likely relevant Evaluates the clinical and immune effects of the anti-GDF-15 antibody visugromab in combination with nivolumab in cancer patients, measuring T cell infiltration and activation. visugromab; nivolumab; anti-PD-1; anti-PD-L1 Patient non-small cell lung cancer, urothelial cancer visugromab 0/0/0; nivolumab 1/2/4; anti-PD-1 14/36/0; anti-PD-L1 0/15/0 Awaiting curator check
39664002 2025 Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti-Tumor Immune Response. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study tests a catalytic hydrogel combined with anti-PD-L1 immunotherapy in in vitro and in vivo HCC models and evaluates the resulting antitumor immune response. DA-COD-OD-HCS catalytic hydrogel; anti-PD-L1 immunotherapy Animal hepatocellular carcinoma (HCC) DA-COD-OD-HCS catalytic hydrogel 0/0/0; anti-PD-L1 immunotherapy 0/0/0 Awaiting curator check
39672166 2025 Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer cell Likely relevant The study uses genetic knockout and pharmaceutical knockdown to test CD28 function alongside anti-PD-1, measuring dendritic cell infiltration and CD8+ T cell activation. anti-PD-1 Animal triple-negative breast cancer anti-PD-1 14/36/0 Awaiting curator check
39690741 2025 In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors. Molecular therapy : the journal of the American Society of Gene Therapy Likely relevant The study tests an engineered oncolytic adenovirus and combination therapies (gemcitabine, immune checkpoint blockades, anti-EGFR) in solid tumor animal models, profiling infiltrating immune cells. oncolytic adenovirus AdV-TNFi; gemcitabine; anti-PD-L1; anti-TIGIT; anti-EGFR Animal solid tumors (including pancreatic and colon carcinoma) oncolytic adenovirus AdV-TNFi 0/0/0; gemcitabine 30/23/10; anti-PD-L1 0/15/0; anti-TIGIT 0/0/0 Awaiting curator check
39787217 2025 Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science (New York, N.Y.) Likely relevant The study tests dietary intake/compounds and anti-PD-1 immunotherapy in liver cancer models and measures tumour-specific T cell responses. anti-programmed cell death protein 1; anti-PD-1; ursodeoxycholic acid Animal hepatocellular carcinoma anti-programmed cell death protein 1 0/0/0; anti-PD-1 14/36/0; ursodeoxycholic acid 0/0/0 Awaiting curator check
39809284 2025 Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. Cell metabolism Likely relevant The study tests anti-CTLA-4 immunotherapy in mouse tumor models while examining immunomodulatory mechanisms involving itaconate transporter SLC13A3 and PD-L1. anti-CTLA-4 Animal syngeneic mouse tumor models anti-CTLA-4 1/10/7 Awaiting curator check
39815258 2025 PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer. Cell communication and signaling : CCS Likely relevant The study experimentally tests anticancer/antiplatelet drugs (aspirin, PD-L1 mAb) in mouse models of colorectal cancer and measures their effects on CD8+ T cell immunity and PD-L1 expression. aspirin; PD-L1 mAb Animal colorectal cancer aspirin 0/0/0; PD-L1 mAb 0/0/0 Awaiting curator check
39919737 2025 Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer cell Likely relevant The study tests named anticancer drugs (paclitaxel, nab-paclitaxel, atezolizumab) in human patients and murine models, and measures their effects on immune cell populations and activation. paclitaxel; nab-paclitaxel; atezolizumab; anti-PD-L1 antibody Mixed triple-negative breast cancer paclitaxel 21/5/8; nab-paclitaxel 0/0/0; atezolizumab 0/0/4; anti-PD-L1 antibody 0/1/0 Awaiting curator check
39920102 2025 WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis. Nature communications Likely relevant Tests a CAMKII inhibitor combined with anti-PD-1 therapy in a mouse model of liver metastasis and measures CD8+ T cell and macrophage responses. anti-PD-1 Animal colorectal cancer liver metastasis anti-PD-1 14/36/0 Awaiting curator check
39983717 2025 Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. Cell reports. Medicine Likely relevant The study tests methionine intervention and immune checkpoint therapy in murine models and reports drug-induced PD-L1 expression and CD8+ T cell recruitment. methionine intervention; immune checkpoint therapy Animal osteosarcoma methionine intervention 0/0/0; immune checkpoint therapy 0/0/0 Awaiting curator check
39988347 2025 Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma. Journal for immunotherapy of cancer Likely relevant Assesses how targeted delivery of CCL3 modulates immune responses and enhances checkpoint blockade efficacy in preclinical HCC models and human samples. rAAV-Ccl3; immune checkpoint inhibitors Mixed hepatocellular carcinoma rAAV-Ccl3 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
← Previous Page 3 of 15 Next →